Product Code: ETC13267477 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Transthyretin Amyloidosis Treatment Market was valued at USD 0.8 Billion in 2024 and is expected to reach USD 1.2 Billion by 2031, growing at a compound annual growth rate of 5.40% during the forecast period (2025-2031).
The Global Transthyretin Amyloidosis Treatment Market is experiencing significant growth due to increased awareness and diagnosis of this rare disease. Transthyretin amyloidosis is a progressive condition that affects various organs in the body, leading to organ dysfunction and failure. The market is driven by the development of novel therapies, including gene silencing drugs and small molecule inhibitors, aimed at slowing the progression of the disease and improving patient outcomes. Additionally, collaborations between pharmaceutical companies and research institutions are boosting research efforts in this field. The market is highly competitive, with key players investing in research and development to bring innovative treatments to market. Factors such as rising prevalence of transthyretin amyloidosis and expanding healthcare infrastructure in emerging economies are expected to further drive market growth in the coming years.
The Global Transthyretin Amyloidosis Treatment Market is experiencing significant growth due to the increasing prevalence of the disease and advancements in treatment options. The market is witnessing a shift towards targeted therapies such as gene silencing and gene editing techniques, offering more promising outcomes for patients. Additionally, the rising investment in research and development activities by pharmaceutical companies to develop innovative treatments is creating lucrative opportunities in the market. The introduction of novel therapies, along with the expanding pipeline of potential drugs, is expected to drive market growth further. Moreover, the increasing awareness about transthyretin amyloidosis among healthcare providers and patients is also contributing to market expansion. Overall, the market presents a promising outlook for stakeholders looking to capitalize on the growing demand for effective treatment options.
The Global Transthyretin Amyloidosis Treatment Market faces several challenges, including limited awareness among healthcare professionals and patients about the disease, resulting in delayed diagnosis and treatment initiation. Additionally, the high cost of treatment options such as gene-silencing therapies poses a barrier to access for many patients, particularly in developing regions. The complexity of the disease, which can manifest in various forms and affect multiple organ systems, also presents challenges in developing effective treatments that target different aspects of the condition. Furthermore, the lack of approved disease-modifying therapies for certain subtypes of transthyretin amyloidosis underscores the need for ongoing research and development efforts to address unmet medical needs in this space.
The Global Transthyretin Amyloidosis Treatment Market is primarily driven by factors such as increasing awareness about the disease, advancements in diagnostic techniques, and a rising number of clinical trials for novel treatment options. Additionally, the growing prevalence of transthyretin amyloidosis globally, especially among the aging population, is fueling the demand for effective treatment options. Furthermore, collaborations between pharmaceutical companies and research institutions to develop innovative therapies, along with government initiatives to promote research and development in rare diseases, are contributing to the market growth. The introduction of gene-silencing therapies and the potential for personalized medicine approaches are also expected to drive market expansion in the coming years.
Government policies related to the Global Transthyretin Amyloidosis Treatment Market typically focus on ensuring access to affordable and effective treatments, promoting research and development for innovative therapies, and regulating the approval and commercialization of drugs. Regulatory bodies such as the FDA in the United States and the EMA in Europe play a crucial role in evaluating the safety and efficacy of treatments for transthyretin amyloidosis. Government initiatives may also include funding for research, supporting clinical trials, and providing incentives for pharmaceutical companies to invest in developing treatments for this rare disease. Additionally, policies may address issues related to insurance coverage, reimbursement mechanisms, and patient access to specialized care centers for diagnosis and treatment. Overall, government policies aim to facilitate the development and availability of treatments for transthyretin amyloidosis while ensuring patient safety and affordability.
The Global Transthyretin Amyloidosis Treatment Market is expected to witness significant growth in the coming years due to the increasing prevalence of the disease, advancements in medical technology, and rising awareness among healthcare professionals and patients. The market is projected to be driven by the introduction of novel therapies, including gene-silencing drugs and monoclonal antibodies, which offer potential for improved outcomes and disease management. Additionally, collaborations between pharmaceutical companies and research institutions for the development of innovative treatment options are likely to further propel market growth. With the growing emphasis on early diagnosis and personalized medicine, the Global Transthyretin Amyloidosis Treatment Market is anticipated to expand rapidly, providing opportunities for market players to invest in research and development efforts to meet the evolving needs of patients worldwide.
In the global Transthyretin Amyloidosis Treatment market, North America holds a significant share due to the high prevalence of the disease and the presence of advanced healthcare infrastructure. Europe follows closely, with a growing focus on research and development in treatment options. Asia is projected to witness substantial growth, driven by increasing awareness, improving healthcare facilities, and rising cases of transthyretin amyloidosis in countries like Japan and China. The Middle East and Africa region is expected to show moderate growth, with improving access to treatment options. Latin America is also anticipated to experience growth, supported by advancements in healthcare and increasing investments in the pharmaceutical sector. Overall, the global Transthyretin Amyloidosis Treatment market is poised for expansion across various regions, with each offering unique opportunities and challenges.
Global Transthyretin Amyloidosis Treatment Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Transthyretin Amyloidosis Treatment Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Transthyretin Amyloidosis Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Global Transthyretin Amyloidosis Treatment Market - Industry Life Cycle |
3.4 Global Transthyretin Amyloidosis Treatment Market - Porter's Five Forces |
3.5 Global Transthyretin Amyloidosis Treatment Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Transthyretin Amyloidosis Treatment Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.7 Global Transthyretin Amyloidosis Treatment Market Revenues & Volume Share, By Therapy, 2021 & 2031F |
3.8 Global Transthyretin Amyloidosis Treatment Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.9 Global Transthyretin Amyloidosis Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Global Transthyretin Amyloidosis Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Transthyretin Amyloidosis Treatment Market Trends |
6 Global Transthyretin Amyloidosis Treatment Market, 2021 - 2031 |
6.1 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By ATTR-PN, 2021 - 2031 |
6.1.3 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By ATTR-CM, 2021 - 2031 |
6.2 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Therapy, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Targeted Therapy, 2021 - 2031 |
6.2.3 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By OnpattroInotersen, 2021 - 2031 |
6.2.4 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Vyndaqel/Vyndamax, 2021 - 2031 |
6.2.5 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Supportive Therapy, 2021 - 2031 |
6.2.6 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Pipeline Therapy, 2021 - 2031 |
6.3 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Hereditary Transthyretin Amyloidosis, 2021 - 2031 |
6.3.3 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Polyneuropathy, 2021 - 2031 |
6.3.4 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Cardiomyopathy, 2021 - 2031 |
6.3.5 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Mixed Type, 2021 - 2031 |
6.3.6 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Wild Type Amyloidosis, 2021 - 2031 |
6.4 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Hospital Pharmacies, 2021 - 2031 |
6.4.3 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Specialty Pharmacies, 2021 - 2031 |
6.4.4 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Retail Pharmacies, 2021 - 2031 |
6.4.5 Global Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Online Pharmacies, 2021 - 2031 |
7 North America Transthyretin Amyloidosis Treatment Market, Overview & Analysis |
7.1 North America Transthyretin Amyloidosis Treatment Market Revenues & Volume, 2021 - 2031 |
7.2 North America Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Type, 2021 - 2031 |
7.4 North America Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Therapy, 2021 - 2031 |
7.5 North America Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
7.6 North America Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
8 Latin America (LATAM) Transthyretin Amyloidosis Treatment Market, Overview & Analysis |
8.1 Latin America (LATAM) Transthyretin Amyloidosis Treatment Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Type, 2021 - 2031 |
8.4 Latin America (LATAM) Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Therapy, 2021 - 2031 |
8.5 Latin America (LATAM) Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
8.6 Latin America (LATAM) Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
9 Asia Transthyretin Amyloidosis Treatment Market, Overview & Analysis |
9.1 Asia Transthyretin Amyloidosis Treatment Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Type, 2021 - 2031 |
9.4 Asia Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Therapy, 2021 - 2031 |
9.5 Asia Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
9.6 Asia Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
10 Africa Transthyretin Amyloidosis Treatment Market, Overview & Analysis |
10.1 Africa Transthyretin Amyloidosis Treatment Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Type, 2021 - 2031 |
10.4 Africa Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Therapy, 2021 - 2031 |
10.5 Africa Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
10.6 Africa Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
11 Europe Transthyretin Amyloidosis Treatment Market, Overview & Analysis |
11.1 Europe Transthyretin Amyloidosis Treatment Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Type, 2021 - 2031 |
11.4 Europe Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Therapy, 2021 - 2031 |
11.5 Europe Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
11.6 Europe Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
12 Middle East Transthyretin Amyloidosis Treatment Market, Overview & Analysis |
12.1 Middle East Transthyretin Amyloidosis Treatment Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Transthyretin Amyloidosis Treatment Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Type, 2021 - 2031 |
12.4 Middle East Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Therapy, 2021 - 2031 |
12.5 Middle East Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
12.6 Middle East Transthyretin Amyloidosis Treatment Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
13 Global Transthyretin Amyloidosis Treatment Market Key Performance Indicators |
14 Global Transthyretin Amyloidosis Treatment Market - Export/Import By Countries Assessment |
15 Global Transthyretin Amyloidosis Treatment Market - Opportunity Assessment |
15.1 Global Transthyretin Amyloidosis Treatment Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Transthyretin Amyloidosis Treatment Market Opportunity Assessment, By Type, 2021 & 2031F |
15.3 Global Transthyretin Amyloidosis Treatment Market Opportunity Assessment, By Therapy, 2021 & 2031F |
15.4 Global Transthyretin Amyloidosis Treatment Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
15.5 Global Transthyretin Amyloidosis Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
16 Global Transthyretin Amyloidosis Treatment Market - Competitive Landscape |
16.1 Global Transthyretin Amyloidosis Treatment Market Revenue Share, By Companies, 2024 |
16.2 Global Transthyretin Amyloidosis Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |